HRP20100019T1 - Kemijski postupak - Google Patents

Kemijski postupak Download PDF

Info

Publication number
HRP20100019T1
HRP20100019T1 HR20100019T HRP20100019T HRP20100019T1 HR P20100019 T1 HRP20100019 T1 HR P20100019T1 HR 20100019 T HR20100019 T HR 20100019T HR P20100019 T HRP20100019 T HR P20100019T HR P20100019 T1 HRP20100019 T1 HR P20100019T1
Authority
HR
Croatia
Prior art keywords
compound
formula
image
salt
base
Prior art date
Application number
HR20100019T
Other languages
English (en)
Croatian (hr)
Inventor
Blixt J�rgen
David Golden Michael
John Hogan Philip
Michael Glanville Martin David
Joseph Montgomery Francis
Patel Zakariya
David Pittam John
Joseph Sependa George
John Squire Christopher
Cartwright Alexander Wright Nicholas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100019(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20100019T1 publication Critical patent/HRP20100019T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20100019T 2005-09-30 2006-09-27 Kemijski postupak HRP20100019T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519879.1A GB0519879D0 (en) 2005-09-30 2005-09-30 Chemical process
PCT/GB2006/003587 WO2007036713A2 (en) 2005-09-30 2006-09-27 Chemical process

Publications (1)

Publication Number Publication Date
HRP20100019T1 true HRP20100019T1 (hr) 2010-02-28

Family

ID=35395001

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20100019T HRP20100019T1 (hr) 2005-09-30 2006-09-27 Kemijski postupak
HR20100620T HRP20100620T1 (hr) 2005-09-30 2010-11-16 Kemijski in situ postupak sulfoniranja

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20100620T HRP20100620T1 (hr) 2005-09-30 2010-11-16 Kemijski in situ postupak sulfoniranja

Country Status (31)

Country Link
US (8) US8163926B2 (de)
EP (2) EP2053048B8 (de)
JP (2) JP5213715B2 (de)
KR (1) KR101307641B1 (de)
CN (3) CN102503898B (de)
AR (1) AR055671A1 (de)
AT (2) ATE448218T1 (de)
AU (1) AU2006296367B2 (de)
BR (1) BRPI0616715A2 (de)
CA (2) CA2624045C (de)
CY (2) CY1110275T1 (de)
DE (2) DE602006010428D1 (de)
DK (2) DK1943240T3 (de)
ES (2) ES2350513T3 (de)
GB (1) GB0519879D0 (de)
HR (2) HRP20100019T1 (de)
IL (2) IL190172A (de)
ME (2) ME01466B (de)
MY (2) MY145540A (de)
NO (1) NO342152B1 (de)
NZ (2) NZ593930A (de)
PL (2) PL2053048T3 (de)
PT (2) PT1943240E (de)
RS (2) RS51515B (de)
RU (1) RU2448102C2 (de)
SG (1) SG165416A1 (de)
SI (2) SI2053048T1 (de)
TW (2) TWI328580B (de)
UY (1) UY29824A1 (de)
WO (1) WO2007036713A2 (de)
ZA (1) ZA200802416B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4608215B2 (ja) * 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EP2404595B1 (de) * 2011-09-01 2015-08-05 Symrise AG Verfahren zur Herstellung von Indanon-Derivaten
ES2678697T3 (es) * 2012-08-15 2018-08-16 Glaxo Group Limited Proceso químico
CN104098544A (zh) * 2013-04-07 2014-10-15 浙江九洲药物科技有限公司 一种凡德他尼的制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870083A (en) * 1987-11-24 1989-09-26 Merrell Dow Pharmaceuticals Inc. 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja) 1989-05-31 1998-12-02 川研ファインケミカル株式会社 ピペリジンカルボン酸類の製造方法
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
WO1992017475A1 (en) 1991-03-28 1992-10-15 Pfizer Inc. Heterocyclic-cyclic amine derivatives
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5624926A (en) 1993-02-18 1997-04-29 Kyowa Hakko Kogyo Co., Ltd. Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
HUT74870A (en) 1993-05-26 1997-02-28 Syntex Inc Process for producing 1-phenylalkanone 5-ht4 receptor ligands and pharmaceutical compositions containing them
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE170174T1 (de) * 1994-01-13 1998-09-15 Merck Sharp & Dohme Gem-bissubstituierte azazyclische tachykinin- antagonisten
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
KR100960827B1 (ko) 2001-12-20 2010-06-08 오에스아이 파마슈티컬스, 인코포레이티드 피롤로피리미딘 Ａ₂ｂ 선택성 길항 화합물, 그의 합성방법 및 용도
JP4608215B2 (ja) 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
AU2003207291A1 (en) 2002-02-06 2003-09-02 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
KR20050056190A (ko) 2002-08-09 2005-06-14 아스트라제네카 아베 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
PT1592423E (pt) 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
EP1648465B1 (de) 2003-07-10 2010-08-25 AstraZeneca AB Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
ES2335435T3 (es) 2010-03-26
JP2013063998A (ja) 2013-04-11
US20160185754A1 (en) 2016-06-30
JP5213715B2 (ja) 2013-06-19
AR055671A1 (es) 2007-08-29
KR20080049114A (ko) 2008-06-03
SG165416A1 (en) 2010-10-28
HRP20100620T1 (hr) 2010-12-31
CN102503898A (zh) 2012-06-20
US8163926B2 (en) 2012-04-24
PL2053048T3 (pl) 2011-03-31
JP5654546B2 (ja) 2015-01-14
CA2624045A1 (en) 2007-04-05
RU2448102C2 (ru) 2012-04-20
NO20081267L (no) 2008-04-30
AU2006296367B2 (en) 2011-08-11
PL1943240T3 (pl) 2010-04-30
ME01531B (me) 2014-04-20
EP2053048B8 (de) 2011-09-21
CN102503933B (zh) 2014-06-25
UY29824A1 (es) 2007-04-30
US20140378684A1 (en) 2014-12-25
AU2006296367A1 (en) 2007-04-05
RS51515B (sr) 2011-06-30
SI1943240T1 (sl) 2010-02-26
EP1943240A2 (de) 2008-07-16
EP1943240B1 (de) 2009-11-11
DE602006010428D1 (de) 2009-12-24
CY1110887T1 (el) 2015-06-10
EP2053048A1 (de) 2009-04-29
DK2053048T3 (da) 2010-11-29
US20090203905A1 (en) 2009-08-13
CA2624045C (en) 2012-05-22
PT2053048E (pt) 2010-11-10
US20120095229A1 (en) 2012-04-19
EP2053048B1 (de) 2010-09-15
WO2007036713A3 (en) 2007-06-14
US20240150317A1 (en) 2024-05-09
IL190172A0 (en) 2008-08-07
NZ566566A (en) 2011-08-26
TW201018660A (en) 2010-05-16
US8865899B2 (en) 2014-10-21
RU2008116573A (ru) 2009-11-10
MY145540A (en) 2012-02-29
IL227574A (en) 2015-08-31
MY149834A (en) 2013-10-31
NZ593930A (en) 2013-02-22
TWI328580B (en) 2010-08-11
US20190263782A1 (en) 2019-08-29
US20180118716A1 (en) 2018-05-03
HK1130478A1 (en) 2009-12-31
ME01466B (me) 2014-04-20
CN102503898B (zh) 2015-03-25
TWI424991B (zh) 2014-02-01
US10344015B2 (en) 2019-07-09
ATE448218T1 (de) 2009-11-15
BRPI0616715A2 (pt) 2011-06-28
ES2350513T3 (es) 2011-01-24
CY1110275T1 (el) 2015-01-14
TW200745036A (en) 2007-12-16
US20220033377A1 (en) 2022-02-03
NO342152B1 (no) 2018-04-03
ATE481399T1 (de) 2010-10-15
ZA200802416B (en) 2009-01-28
CA2745829C (en) 2013-07-02
CN101277948A (zh) 2008-10-01
JP2009510039A (ja) 2009-03-12
PT1943240E (pt) 2010-01-11
CN102503933A (zh) 2012-06-20
US9815816B2 (en) 2017-11-14
DK1943240T3 (da) 2010-03-01
IL190172A (en) 2014-05-28
DE602006017004D1 (de) 2010-10-28
SI2053048T1 (sl) 2010-12-31
CN101277948B (zh) 2013-03-13
RS51263B (sr) 2010-12-31
KR101307641B1 (ko) 2013-09-12
HK1122553A1 (en) 2009-05-22
CA2745829A1 (en) 2007-04-05
GB0519879D0 (en) 2005-11-09
WO2007036713A2 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
EP3057942B1 (de) 1,4-cyclohexylaminderivate und verfahren zur herstellung davon
ES2563954T3 (es) Derivados de ftalazina como inhibidores de PARP
ES2890492T3 (es) Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C
US20030181466A1 (en) Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
AP1305A (en) Process for preparing a protected 4-aminomethyl-pyrrolidin-3-one.
JP4560293B2 (ja) 医薬上有効な化合物（グラニセトロン）の製造方法
HRP20100019T1 (hr) Kemijski postupak
AU2012319291A1 (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein
RS54248B1 (sr) Nova jedinjenja kao ligandi histamin h3 receptora
JP2011507921A (ja) ６−置換−１−（２ｈ）−イソキノリノンの製造法
KR20040032639A (ko) 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법
CN104016877B (zh) 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
JP5585822B2 (ja) 光学活性ニペコチン酸誘導体の製造方法
US7202360B2 (en) Method for preparing risperidone
KR102068754B1 (ko) 의약품 합성용 중간체 화합물의 제조 방법
CA2518081A1 (en) New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate
US8093384B2 (en) Processes for the preparation of alfuzosin
WO2013084241A1 (en) Compounds as inhibitors of renin
EP1867635A1 (de) Verfahren zur Herstellung von Remifentanil, seine Zwischenprodukte, die Verwendung von diesen Zwischenprodukten und das Verfahren zur deren Herstellung
JP4790901B2 (ja) ４−アミノ−５−シアノイミダゾール誘導体及びその中間体の製造方法
CN101652357B (zh) 喹诺酮羧酸衍生物的制备方法
KR101752449B1 (ko) 솔리페나신 또는 그 염의 결정형 제조방법, 이에 사용되는 신규 중간체 및 그 제조방법
CN101304980B (zh) 3-(4-哌啶基)-2,3,4,5,-四氢-1,3-苯并二氮杂䓬-2(1h)-酮
US20100280024A1 (en) Renin inhibitors
EP1484321A1 (de) Verfahren zur Herstellung von 1-Methylindazol-3-Carbonsäure